二丁酰环磷腺苷钙联合伊伐布雷定对慢性心力衰竭的疗效
|
摘要
目的研究二丁酰环磷腺苷钙联合伊伐布雷定治疗慢性心力衰竭的效果。方法选择96例慢性心力衰竭患者,随机分为两组。在常规治疗的基础上,对照组采用二丁酰环磷腺苷钙治疗,观察组采用二丁酰环磷腺苷钙联合伊伐布雷定治疗。比较两组的总有效率,治疗前后的心功能、血清学指标。结果观察组的治疗总有效率明显高于对照组(P <0.05);治疗后,两组的NT-pro BNP、HR、CRP明显降低(P <0.05),LVEF明显升高(P <0.05),且观察组的改善幅度大于对照组(P <0.05);治疗期间,两组的头痛、眼内闪光、心动过缓、胆红素升高发生率比较无明显差异(P> 0.05)。结论二丁酰环磷腺苷钙联合伊伐布雷定治疗心衰的效果较佳,能有效改善心功能,降低炎性反应,且安全性较高。
Objective To study the efficacy of dibutyryl cyclic adenosine phosphate combined with ivabradine in the treatment of chronic heart failure. Methods A total of 96 patients with chronic heart failure were selected and randomly divided into a control group and an observation group. On the basis of conventional treatment, the control group was treated with dibutyryl cyclic adenosine phosphate, and the observation group was treated with dibutyr yl cyclic adenosine phosphate combined with ivabradine. The total effective rates, heart functions and serum indexes before and after treatment were compared. Results The total effective rate in the observation group was significantly higher than that in the control group(P < 0.05). After treatment, the NT-pro BNP, HR and CRP in both groups were significantly lower(P < 0.05), while the LVEF was significantly higher(P < 0.05), and more significant in the observation group(P < 0.05). During treatment, there was no difference in the incidences of headache, intraocular flash, bradycardia and increased bilirubin between the two groups(P > 0.05). Conclusion Dibutyryl cyclic adenosine phosphate combined with ivabradine is a better and safer resort to treat heart failure by effectively improving heart function and inhibiting inflammatory reaction.
Objective To study the efficacy of dibutyryl cyclic adenosine phosphate combined with ivabradine in the treatment of chronic heart failure. Methods A total of 96 patients with chronic heart failure were selected and randomly divided into a control group and an observation group. On the basis of conventional treatment, the control group was treated with dibutyryl cyclic adenosine phosphate, and the observation group was treated with dibutyr yl cyclic adenosine phosphate combined with ivabradine. The total effective rates, heart functions and serum indexes before and after treatment were compared. Results The total effective rate in the observation group was significantly higher than that in the control group(P < 0.05). After treatment, the NT-pro BNP, HR and CRP in both groups were significantly lower(P < 0.05), while the LVEF was significantly higher(P < 0.05), and more significant in the observation group(P < 0.05). During treatment, there was no difference in the incidences of headache, intraocular flash, bradycardia and increased bilirubin between the two groups(P > 0.05). Conclusion Dibutyryl cyclic adenosine phosphate combined with ivabradine is a better and safer resort to treat heart failure by effectively improving heart function and inhibiting inflammatory reaction.
引文
[1]董洪玲,王中鲁,张亮,等.慢性心力衰竭的治疗进展[J].中国循证心血管医学杂志, 2017, 9(2):246-248.
[2]李彦.美托洛尔与卡维地洛治疗慢性心力衰竭的临床效果[J].中国医药导报, 2017, 14(4):90-93.
[3]黄觊,钱海燕,胡志成,等.伊伐布雷定对老年慢性心力衰竭患者的疗效及其对胱抑素C的影响[J].疑难病杂志, 2017, 16(6):545-549.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35:1076-1095.
[5]冯卫涛,李薇,栾荣华.卡维地洛联合缬沙坦治疗慢性心力衰竭的临床效果[J].心血管康复医学杂志, 2017, 26(3):310-313.
[6]程志祥,冯飞,覃辉.福辛普利钠联合环磷腺苷葡胺治疗慢性心力衰竭的临床研究[J].现代药物与临床, 2018, 33(10):85-88.
[7]盛洋,郑学敏,王伟,等.酒石酸美托洛尔片联合左卡尼汀注射剂治疗慢性心力衰竭的临床研究[J].中国临床药理学杂志,2018, 34(4):410-413.
[8]宁雕,陈素芹.二丁酰环磷腺苷联合左西孟旦治疗慢性心力衰竭的临床研究[J].现代药物与临床, 2018, 33(5):55-58.
[9]马建林,王晓红,李春梅,等.依普利酮与伊伐布雷定治疗慢性心力衰竭疗效及其对血TNF-α、IL-6、BNP水平的影响[J].疑难病杂志, 2017, 16(10):985-988.
[10]程丽丹,江一唱,晏凯利,等.伊伐布雷定联合常规治疗慢性心力衰竭的疗效与安全性观察[J].药物流行病学杂志, 2017,26(9):9-12.
[11]陆铭,蒋庆渊,刘春兰,等.心率控制对慢性心力衰竭患者炎症因子及心功能的影响[J].实用医学杂志, 2017, 33(19):84-88.
[12] Grande D, Iacoviello M, Aspromonte N. The effects of heart rate control in chronic heart failure with reduced ejection fraction[J].Heart Fail Rev, 2018, 23(4):527-535.
[13]洪飞,汪磊.慢性心力衰竭患者血清CA125、hs-CRP和TNF-α水平及其与心功能的关系[J].中国医科大学学报, 2017, 46(9):787-790.
[2]李彦.美托洛尔与卡维地洛治疗慢性心力衰竭的临床效果[J].中国医药导报, 2017, 14(4):90-93.
[3]黄觊,钱海燕,胡志成,等.伊伐布雷定对老年慢性心力衰竭患者的疗效及其对胱抑素C的影响[J].疑难病杂志, 2017, 16(6):545-549.
[4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35:1076-1095.
[5]冯卫涛,李薇,栾荣华.卡维地洛联合缬沙坦治疗慢性心力衰竭的临床效果[J].心血管康复医学杂志, 2017, 26(3):310-313.
[6]程志祥,冯飞,覃辉.福辛普利钠联合环磷腺苷葡胺治疗慢性心力衰竭的临床研究[J].现代药物与临床, 2018, 33(10):85-88.
[7]盛洋,郑学敏,王伟,等.酒石酸美托洛尔片联合左卡尼汀注射剂治疗慢性心力衰竭的临床研究[J].中国临床药理学杂志,2018, 34(4):410-413.
[8]宁雕,陈素芹.二丁酰环磷腺苷联合左西孟旦治疗慢性心力衰竭的临床研究[J].现代药物与临床, 2018, 33(5):55-58.
[9]马建林,王晓红,李春梅,等.依普利酮与伊伐布雷定治疗慢性心力衰竭疗效及其对血TNF-α、IL-6、BNP水平的影响[J].疑难病杂志, 2017, 16(10):985-988.
[10]程丽丹,江一唱,晏凯利,等.伊伐布雷定联合常规治疗慢性心力衰竭的疗效与安全性观察[J].药物流行病学杂志, 2017,26(9):9-12.
[11]陆铭,蒋庆渊,刘春兰,等.心率控制对慢性心力衰竭患者炎症因子及心功能的影响[J].实用医学杂志, 2017, 33(19):84-88.
[12] Grande D, Iacoviello M, Aspromonte N. The effects of heart rate control in chronic heart failure with reduced ejection fraction[J].Heart Fail Rev, 2018, 23(4):527-535.
[13]洪飞,汪磊.慢性心力衰竭患者血清CA125、hs-CRP和TNF-α水平及其与心功能的关系[J].中国医科大学学报, 2017, 46(9):787-790.